Literature DB >> 17565579

Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience.

Michael A Zimmerman1, James F Trotter, Michael Wachs, Thomas Bak, Jeffrey Campsen, Franklin Wright, Tracy Steinberg, William Bennett, Igal Kam.   

Abstract

Orthotopic liver transplantation (OLT) is increasingly being applied for cure in patients with cirrhosis and concomitant hepatocellular carcinoma (HCC). In recipients with limited tumor burden, OLT achieves reasonable long-term outcome. This study sought to identify clinical and pathologic variables predictive of long-term disease-free survival and the presence of vascular invasion. From 1992 to 2006, 130 patients underwent OLT for cirrhosis and HCC. Malignancy was diagnosed in 107 patients prior to OLT and in 23 patients on pathologic examination of the explant. Nine clinical and pathologic variables were considered including: TNM stage, nodularity, vascular invasion, Milan criteria, incidental lesion, differentiation, tumor size, preOLT transarterial chemoembolization (TACE), and administration of sirolimus-based immunosuppression. The overall incidence of HCC recurrence was 17% with the majority (82%) being stage III. Cumulatively, tumor recurrence-free survival (RFS) is 84, 74, and 67% at 1, 3, and 5 years respectively. Independent predictors of RFS included stage III and poorly differentiated lesions (P<0.05). Furthermore, stage III tumors and those >3.5 cm in size were predictive of vascular invasion. Importantly, preOLT, TACE and postOLT sirolimus had no influence on survival. Pathologic variables including tumor stage and grade have a significant impact on outcome. Importantly, it seems that TACE and sirolimus had no beneficial effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565579     DOI: 10.1111/j.1432-2277.2007.00505.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  12 in total

1.  Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Authors:  Pratima Sharma; Kathy Welch; Hero Hussain; Shawn J Pelletier; Robert J Fontana; Jorge Marrero; Robert M Merion
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  [National S3 guidelines on hepatocellular carcinoma].

Authors:  C M Sommer; U Stampfl; H U Kauczor; P L Pereira
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

3.  Prediction of histological grade of hepatocellular carcinoma using quantitative diffusion-weighted MRI: a retrospective multivendor study.

Authors:  Yusuke Ogihara; Yoshio Kitazume; Yoshihiro Iwasa; Shinichi Taura; Yoshiro Himeno; Tomo Kimura; Seishi Sawano; Shigehiko Terada; Minoru Tanabe; Yukihisa Saida; Ukihide Tateishi
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

4.  Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list.

Authors:  Constantine Frangakis; Jean-Francois Geschwind; Daniel Kim; Yong Chen; Ayman Koteish; Kelvin Hong; Eleni Liapi; Christos S Georgiades
Journal:  Cardiovasc Intervent Radiol       Date:  2010-12-30       Impact factor: 2.740

Review 5.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

6.  Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.

Authors:  Nadim Mahmud; Abraham Shaked; Kim M Olthoff; David S Goldberg
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

7.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

8.  A Decade of Experience Using mTor Inhibitors in Liver Transplantation.

Authors:  Jeffrey Campsen; Michael A Zimmerman; Susan Mandell; Maria Kaplan; Igal Kam
Journal:  J Transplant       Date:  2011-03-15

Review 9.  Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.

Authors:  Robert S Rahimi; James F Trotter
Journal:  Ann Gastroenterol       Date:  2015 Jul-Sep

Review 10.  Current status of multimodal & combination therapy for hepatocellular carcinoma.

Authors:  Jian Yang; Lunan Yan; Wentao Wang
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.